QL1706
Clinical trials for QL1706 explained in plain language.
Never miss a new study
Get alerted when new QL1706 trials appear
Sign up with your email to follow new studies for QL1706, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo may let some breast cancer patients skip harsh chemo
Disease control Not yet recruitingThis study tests a new drug (QL1706) combined with chemotherapy before surgery in 40 people with early triple-negative breast cancer. The goal is to see if some patients can avoid a type of chemo called anthracyclines, which can harm the heart. After four cycles of treatment, tho…
Matched conditions: QL1706
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated May 17, 2026 05:35 UTC
-
New combo therapy shows promise against tough colon cancer
Disease control Not yet recruitingThis study tests a new drug combination (QL1706 plus XELOX) given before surgery for people with stage III colon cancer that is stable (pMMR/MSS). About 21 participants will receive four cycles of treatment, then have surgery. The main goal is to see if the cancer disappears comp…
Matched conditions: QL1706
Phase: PHASE2 • Sponsor: Qilu Hospital of Shandong University • Aim: Disease control
Last updated May 12, 2026 13:41 UTC
-
New drug combo aims to shrink esophageal tumors
Disease control Not yet recruitingThis study tests a new drug called QL1706, which helps the immune system fight cancer, combined with two chemotherapy drugs (nab-paclitaxel and cisplatin) as a first treatment for people with advanced or spread esophageal cancer. About 50 adults who have not had prior treatment f…
Matched conditions: QL1706
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Henan University of Science and Technology • Aim: Disease control
Last updated May 04, 2026 16:21 UTC